# Phase 2 schizophrenia trials recruiting: 27 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 27 trials in phase 2 for schizophrenia that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 schizophrenia trials: 27 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/schizophrenia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 27
- Recruiting or not yet: 27
- Read on: November 19, 2026

## Trials

The 25 newest of 27, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 30, 2026 | NCT07850102 | Brain Imaging of DSP-2342 | Johns Hopkins University | Phase 2 | Not yet recruiting | SCHIZOPHRENIA 1 (Disorder) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850102) |
| August 12, 2026 | NCT07759895 | Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia | Sponsor not shown (see the record) | Phase 2 | Recruiting | Schizoaffecitve Disorder, Schizophrenia and Schizoaffective Disorder, Schizophrenia and Predominant Negative Symptoms | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07759895) |
| July 15, 2026 | NCT07703956 | Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults | Vigonvita Life Sciences | Phase 2 | Not yet recruiting | Schizophrenia | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07703956) |
| July 2, 2026 | NCT07680946 | Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia | TG Therapeutics, Inc. | Phase 2 | Recruiting | Schizophrenia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07680946) |
| May 18, 2026 | NCT07592169 | Confirmatory Trial of Gamma Neurofeedback to Improve Working Memory in Schizophrenia | University of California, San Diego | Phase 2 | Recruiting | SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07592169) |
| March 12, 2026 | NCT07467993 | Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia | Novartis Pharmaceuticals | Phase 2 | Recruiting | Schizophrenia | 142 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07467993) |
| March 10, 2026 | NCT07459647 | A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia | MapLight Therapeutics | Phase 2 | Recruiting | Schizophrenia | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07459647) |
| February 13, 2026 | NCT07410507 | A Study of Brenipatide in Adult Participants With Schizophrenia | Eli Lilly and Company | Phase 2 | Recruiting | Schizophrenia | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410507) |
| February 9, 2026 | NCT07396870 | A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia | Luye Pharma Group Ltd. | Phase 2 | Not yet recruiting | Schizophrenia | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07396870) |
| December 17, 2025 | NCT07288333 | Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia | Neurocrine Biosciences | Phase 2 | Recruiting | Schizophrenia | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07288333) |
| August 28, 2025 | NCT07145918 | A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With... | AbbVie | Phase 2 | Recruiting | Schizophrenia | 268 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07145918) |
| August 14, 2025 | NCT07122895 | Sex Differences in NMDA-enhancing Treatment of Schizophrenia | China Medical University Hospital | Phase 2 | Recruiting | Schizophrenia | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07122895) |
| April 22, 2025 | NCT06939088 | Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder | Sponsor not shown (see the record) | Phase 2 | Recruiting | Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence, Alcoholism, Schizophrenia Disorders, Schizophrenia... | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06939088) |
| February 12, 2025 | NCT06821945 | A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia | Boryung Pharmaceutical Co., Ltd | Phase 2 | Recruiting | Schizophrenia | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06821945) |
| August 27, 2024 | NCT06574360 | Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia | China Medical University Hospital | Phase 2 | Recruiting | Schizophrenia | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06574360) |
| July 16, 2024 | NCT06502964 | Study of ALTO-101 in Patients With Schizophrenia | Alto Neuroscience | Phase 2 | Recruiting | Schizophrenia, Cognitive Impairment | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06502964) |
| April 19, 2024 | NCT06376734 | Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness | Brigham and Women's Hospital | Phase 2 | Recruiting | Major Depressive Disorder, Obsessive-Compulsive Disorder, Schizophrenia, Generalized Anxiety Disorder, Mood Disorders... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06376734) |
| April 2, 2024 | NCT06340789 | Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate | National Cheng-Kung University Hospital | Phase 2 | Recruiting | Symptom, Cognitive, Schizophrenia, Schizo Affective Disorder | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06340789) |
| March 18, 2024 | NCT06315972 | Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity | LMU Klinikum | Phase 2 | Not yet recruiting | Schizophrenia | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06315972) |
| September 1, 2023 | NCT06021197 | NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia | China Medical University Hospital | Phase 2 | Recruiting | Schizophrenia | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06021197) |
| March 21, 2023 | NCT05778591 | Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia | University of California, Los Angeles | Phase 2 | Recruiting | Schizophrenia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05778591) |
| February 15, 2022 | NCT05240976 | Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia | China Medical University Hospital | Phase 2 | Recruiting | Schizophrenia | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05240976) |
| September 22, 2021 | NCT05052853 | Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer | China Medical University Hospital | Phase 2 | Recruiting | Prodromal Schizophrenia | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05052853) |
| July 13, 2021 | NCT04959201 | Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia | China Medical University Hospital | Phase 2 | Recruiting | Schizophrenia | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04959201) |
| June 8, 2021 | NCT04917302 | Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia | China Medical University Hospital | Phase 2 | Recruiting | Schizophrenia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04917302) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| China Medical University Hospital | 8 |
| Sheppard Pratt Health System | 1 |
| Johns Hopkins University | 1 |
| University of California, San Diego | 1 |
| [Neurocrine Biosciences](https://specstream.ai/data/clinical-trials/company/neurocrine-biosciences) | 1 |
| [Boryung Pharmaceutical Co., Ltd](https://specstream.ai/data/clinical-trials/company/boryung-pharmaceutical-co-ltd) | 1 |
| Brigham and Women's Hospital | 1 |
| National Cheng-Kung University Hospital | 1 |
| Alto Neuroscience | 1 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 1 |
| [TG Therapeutics, Inc.](https://specstream.ai/data/clinical-trials/company/tg-therapeutics-inc) | 1 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 1 |
| MapLight Therapeutics | 1 |
| LMU Klinikum | 1 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |
| [Luye Pharma Group Ltd.](https://specstream.ai/data/clinical-trials/company/luye-pharma-group-ltd) | 1 |
| [Vigonvita Life Sciences](https://specstream.ai/data/clinical-trials/company/vigonvita-life-sciences) | 1 |
| University of California, Los Angeles | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 11 |
| Taiwan | 10 |
| China | 3 |
| Bulgaria | 2 |
| Denmark | 1 |
| Romania | 1 |
| United Kingdom | 1 |
| South Korea | 1 |
| Argentina | 1 |
| Brazil | 1 |
| India | 1 |
| Japan | 1 |
| Israel | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Infectious disease clinics in the United States](https://specstream.ai/data/businesses/infectious-disease-clinics/united-states)
- [Plumbers in the United States](https://specstream.ai/data/businesses/plumbers/united-states)
- [Valet services in the United States](https://specstream.ai/data/businesses/valet-services/united-states)
- [Business consulting firms in the United States](https://specstream.ai/data/businesses/business-consulting-firms/united-states)
- [Fish and chips restaurants in the United States](https://specstream.ai/data/businesses/fish-and-chips-restaurants/united-states)
- [Medical transportation companies in the United States](https://specstream.ai/data/businesses/medical-transportation-companies/united-states)
